CALIDI BIOTHERAPEUTICS INC (CLDI)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.39+2.96%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Calidi plans to file an IND for CLD-401 in Q4 2026. Operating losses improved from -$5.77M to -$4.19M in recent quarters. The company manages cash burn better than before. Positive M&A deals may help growth.
Calidi is losing more money with EPS at -$5.52 for 2026. The stock dropped nearly 50% from its high. Equity sales dilute shareholders and signal cash needs. No revenue is expected soon.
The market prices in continued losses and no revenue growth. Our view sees risk in the cash burn and uncertain drug progress.
Breaks if: excessive dilution or failure to raise needed capital
Breaks if: IND filing is not completed by end of 2026-Q4
operating loss worsens beyond -$4.19M per quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is fragile, with management facing challenges in execution and a high probability of earnings misses.
The market seems to reflect a cautious outlook, given the company's loss-making status and high risk. Expectations may be low, particularly as recent performance has shifted from the upper half to the lower half of its industry.
Fundamentals are likely to remain under pressure due to ongoing net losses and high cash burn. Management's focus on controlling expenses shows some progress, but the elevated risk of missing earnings adds uncertainty.
The thesis hinges on management's ability to execute on key priorities like filing the IND for CLD-401 and advancing the RedTail platform. Additionally, broader sector performance and economic indicators, such as job reports, will significantly influence the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates that the reason to own it has weakened. The next-quarter miss estimate is 74%, which supports this state change.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain disciplined expense management to reduce general and administrative costs and manage cash to support pipeline advancement.
Stated as a priority in 2 of last 2 quarters. Management achieved a $1.5 million (48%) reduction in general and administrative expenses in Q2 2026 compared to Q2 2025, and a $1 million reduction from Q1 2025 to Q1 2026. Despite ongoing net losses around $4 million per quarter, expense discipline shows delivering progress on cost control.
“Reduced general and administrative expenses by $1.5 million, or 48%, in Q2 2026 versus same period in 2025.”
“Demonstrated $1 million reduction in general and administrative expenses from Q1-2025 to Q1-2026.”
Over the next 1 to 3 years, CLDI faces significant challenges that could impact its growth potential. Not investment advice.